Cartesian Therapeutics initiated a phase 1 clinical trial for Descartes-15, a novel mRNA-engineered CAR-T therapy, in relapsed/refractory multiple myeloma patients.
Ractigen Therapeutics' RAG-18, a small activating RNA (saRNA) therapy, has been granted Orphan Drug Designation by the FDA for treating Duchenne and Becker muscular dystrophy.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.